-
Provention Bio's CEO On Identifying Autoimmune Diseases 'Before It's Too Late'
Tuesday, May 5, 2020 - 11:28am | 953Read More...When it comes to treating chronic, immune-mediated diseases, the standard course is to wait for symptoms before beginning treatment. But by that point, it may be too late for intervention. These diseases can silently do irreversible damage, according to Provention Bio Inc (NASDAQ: PRVB) CEO...
-
VTV Therapeutics 'Close To The Finish Line' On What FDA, Diabetes Patients Want: An Adjunct Therapy To Insulin
Wednesday, February 19, 2020 - 11:48am | 899Read More...Steve Holcombe transitioned from telecom to biotech back when vTv Therapeutics Inc (NASDAQ: VTVT) was just a startup. Now, 18 years in, he’s finally seeing the fruits of his labor. “We’re getting close to the finish line,” Holcombe, the CEO of VTV, told Benzinga. “We...
-
VTV Therapeutics Shares Hit 16-Month High After Diabetes Drug Aces Midphase Study
Monday, February 10, 2020 - 12:14pm | 453Read More...Shares of micro-cap biotech vTv Therapeutics Inc (NASDAQ: VTVT) were advancing to their highest level since October 2018 Monday following a clinical readout from the company. Success In Phase 2 For VTV Therapeutics High Point, North Carolina-based vTv said part two of the Phase 2 Simplici-...
-
Eli Lilly CEO Hits Back At Elizabeth Warren, Blames PBMs, Insurance For Blocking Affordable Insulin
Wednesday, December 18, 2019 - 12:07pm | 756Read More...Eli Lilly And Co (NYSE: LLY) CEO David Ricks said Tuesday that U.S. Sen. Elizabeth Warren’s criticism of the cost of the drugmaker's insulin is “nonsense.” Warren Says Eli Lilly Broke Promise On Insulin In a Monday Facebook post, the Democratic presidential candidate denounced...
-
Biotech Stock On The Radar: vTv Therapeutics' Diabetes Pipeline
Tuesday, September 17, 2019 - 4:35pm | 1408Read More...The thinly traded micro-cap biotech vTv Therapeutics Inc (NASDAQ: VTVT) is on investors' radars ahead of a Sept. 18 poster presentation of clinical data. The company is set to present at the European Association for the Study of Diabetes 55th annual meeting with results from the Part...
-
Morgan Stanley: Buy The Dip In Livongo Health
Wednesday, August 28, 2019 - 2:23pm | 404Read More...Shares of Livongo Health Inc (NASDAQ: LVGO) have lost nearly 20% since its late July IPO, and investors should take advantage of the discount valuation, according to Morgan Stanley. The Analyst Ricky Goldwasser upgraded Livongo Health from Equal-weight to Overweight with an unchanged $42 price...
-
Midatech Pharma Rallies On Positive MTX102 Results
Friday, July 19, 2019 - 2:33pm | 260Read More...Midatech Pharma PLC-ADR (NASDAQ: MTP) shares were trading higher Friday after the company announced positive results from a first-in-human study of its MTX102 immuno-tolerizing vaccine product candidate in diabetes. The results showed that MTX102 was well-tolerated, with asymptomatic local...
-
The Science On How Cannabis Could Help Diabetes Patients
Wednesday, October 17, 2018 - 3:28pm | 826Read More...Weed's role as a natural painkiller without the addictive properties of opioids is well-known, as is cannabidiol's helpfulness in combating seizures and anxiety. Studies and evidence support CBD's effectiveness in improving the behavior of children on the autism spectrum...
-
BofA Upgrades Sanofi, Names 3 Growth Drivers For Pharma Stock
Monday, September 10, 2018 - 3:58pm | 358Read More...Sanofi SA (ADR) (NYSE: SNY), is approaching a growth inflection point, according to Bank of America Merrill Lynch. The sell-side firm is projecting 6-percent earnings per share growth for the pharmaceutical company. The Analyst Analyst Graham Parry upgraded Sanofi from Neutral to Buy and...
-
'A New Revolution Of Medicine': Senseonics Brings Automation To Diabetes Care
Monday, July 16, 2018 - 3:09pm | 908Read More...Automation and artificial intelligence are transforming everything from travel to finance to how garage doors are closed. The management of personal health is poised for similar disruption. Fitbit Inc (NYSE: FIT) and Apple Inc. (NASDAQ: AAPL) have taken wearable-based health monitoring mainstream...
-
Valeritas Stock Should More Than Double, Oppenheimer Says
Thursday, July 5, 2018 - 12:41pm | 396Read More...Valeritas Holdings Inc (NASDAQ: VLRX), a medical technology company known for its V-Go Wearable Insulin Delivery device, could more than double in value, according to Oppenheimer. The Analyst Oppenheimer's Steven Lichtman initiated coverage of Valeritas with an Outperform rating and 12- to 18-...
-
Tandem Diabetes Rallies After FDA Approves Insulin Pump With New Technology
Friday, June 22, 2018 - 10:34am | 401Read More...Tandem Diabetes Care Inc (NASDAQ: TNDM) shares were rallying Friday following FDA approval of the company's new insulin pump. Tandem Diabetes were trading up 12.4 percent to $22.83 at the time of publication Friday morning. What Happened The medical device maker...
-
Baird Sees 'Improved Odds' Tandem Diabetes Care Will Survive
Friday, March 23, 2018 - 2:41pm | 418Read More...Tandem Diabetes Care Inc (NASDAQ: TNDM), a medical technology company focused on the treatment of diabetes and insulin infusion therapy, has seen transformed from a "solid competitive" company in mid-2016 to one where it might not survive, according to Baird. But the company may boast the...
-
Eli Lilly's Challenges Leaves Credit Suisse With A 'Sour Taste'
Monday, January 22, 2018 - 11:44am | 373Read More...Analysts at Credit Suisse downgraded Eli Lilly and Co (NYSE: LLY) in October and just three months later, the firm believes another downgrade is warranted. The Analyst Credit Suisse's Vamil Divan downgraded Eli Lilly's stock from Neutral to Underperform with a price target lowered...
-
Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade
Tuesday, January 16, 2018 - 1:06pm | 400Read More...The case for buying shares of Eli Lilly and Co (NYSE: LLY) no longer applies, as an analysis of the company's franchise suggests investors are underappreciating the risk surrounding its biggest diabetes franchise, according to Goldman Sachs. The Analyst Goldman Sachs' Jami Rubin...
